UBS Warburg Cuts Cytyc to 'Hold'

Analyst Ricky Goldwasser says the environment for cervical cancer screening test just got more competitive

UBS Warburg cut Cytyc (CYTC ) to hold from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.